{
    "nct_id": "NCT03597295",
    "official_title": "A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM-202)",
    "inclusion_criteria": "* Ability to comprehend and willingness to sign a written informed consent form.\n* Confirmed diagnosis of locally advanced or metastatic SCAC.\n* Must have received (or been intolerant to or ineligible for) at least 1 prior line of platinum-based chemotherapy and received no more than 2 prior systemic treatments.\n* Must have measurable disease by RECIST v1.1.\n* Eastern Cooperative Oncology Group performance status of 0 to 1.\n* If HIV-positive, then all of the following criteria must also be met: CD4+ count ≥ 300/μL, undetectable viral load, and receiving highly active antiretroviral therapy.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Receipt of anticancer therapy or participation in another interventional clinical study within 21 days before the first administration of study drug; 6 weeks for mitomycin C.\n* Radiotherapy within 14 days of first dose of study treatment with the following caveats: 28 days for pelvic radiotherapy, 6 months for thoracic region radiotherapy that is > 30 Gy.\n* Prior treatment with programmed cell death protein 1 (PD-1) or programmed cell death ligand protein 1 (PD-L1)-directed therapy.\n* Active autoimmune disease requiring systemic immunosuppression.\n* Known central nervous system (CNS) metastases and/or carcinomatous meningitis.\n* Known active hepatitis infection.\n* Active infections requiring systemic therapy.\n* Is pregnant or breastfeeding or is expecting to conceive or father children within the projected duration of the study, from screening through 6 months after the last dose of study drug.",
    "miscellaneous_criteria": ""
}